Gladden Longevity Podcast -- formerly Living Beyond 120 cover image

A Major Tool in Cracking the Code of Aging & Youthfulness - Episode 169

Gladden Longevity Podcast -- formerly Living Beyond 120

00:00

Cancer Adjuvants

With Generation 1, we actually had a 55% objective response and getting tumors to reduce in size. And then with our new Generation 2 and 3, we're pushing closer to 72%. We've got a long way to go because our goal and objective is to get to the 80% mark. But we really need to get more patients and do a lot more design so that we can really tighten up the process.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app